Guardant Health(GH) - 2021 Q4 - Earnings Call Presentation

Financial Performance - Q4 2021 revenue reached $108 million, a 38% year-over-year increase compared to $78 million in Q4 2020 [5, 6] - 2021 annual revenue totaled $374 million [7] compared to $287 million in 2020 [6] - The company anticipates total revenue between $460 million and $470 million for 2022, representing a 24% growth at the midpoint [33] Clinical and Biopharma Growth - Q4 2021 clinical volumes increased by 48% year-over-year [7] - The company has surpassed 100 biopharma partners [5, 12] - Biopharma volume is expected to grow by over 30% in 2022 [33] Product Development and Market Opportunity - The company launched three new products in 2021 [5] - The MRD (Minimal Residual Disease) market presents a $15 billion opportunity [9] - The company is targeting a $20 billion opportunity for CRC (Colorectal Cancer) screening in 2022 and beyond [15] - The multi-cancer screening market represents a $50 billion+ opportunity [30] Global Expansion - The company is building two labs in Europe with partners in Spain and the UK [11] - Guardant360CDx has been submitted for regulatory approval in Japan [11] Cancer Screening Program - ECLIPSE study reached its target enrollment [5, 17] - The company is moving towards multi-cancer opportunity with SHIELD Lung study [29]